CBD Blocked Brain Inflammation Pathways Triggered by Alzheimer's-Related Protein in Cell Study
CBD inhibited both nitric oxide production and iNOS protein expression in neurons exposed to Alzheimer's-associated beta-amyloid protein, working through the p38 MAP kinase and NF-kappaB anti-inflammatory pathways.
Quick Facts
What This Study Found
Researchers tested CBD's effects on neuronal cells (PC12) stimulated with beta-amyloid (1-42), a protein associated with Alzheimer's disease. Exposure to beta-amyloid for 36 hours caused a significant increase in nitrite production, a marker of nitrosative stress.
CBD inhibited both nitrite production and iNOS protein expression in a concentration-dependent manner. The mechanism was traced to two specific pathways: CBD inhibited the phosphorylation of p38 MAP kinase and blocked activation of the transcription factor NF-kappaB, both key mediators of inflammatory responses.
This built on previous work showing CBD has anti-oxidant and anti-apoptotic effects that protect neurons from beta-amyloid toxicity. The finding that CBD also blocks the nitrosative stress pathway adds another potential neuroprotective mechanism.
Key Numbers
CBD concentrations tested: 10^-6 to 10^-4 M. Beta-amyloid stimulation: 1 microgram/mL for 36 hours. CBD inhibited iNOS expression and nitrite production concentration-dependently. Mechanism: p38 MAP kinase and NF-kappaB pathway inhibition.
How They Did This
In vitro cell study using differentiated PC12 neurons. Cells were stimulated with beta-amyloid (1-42) at 1 microgram/mL for 36 hours. CBD tested at concentrations of 10^-6 to 10^-4 M. Nitrite production measured as an indicator of nitric oxide production. iNOS protein expression, p38 MAP kinase phosphorylation, and NF-kappaB activation assessed.
Why This Research Matters
Neuroinflammation is a major component of Alzheimer's disease pathology. Finding that CBD can block specific inflammatory pathways triggered by beta-amyloid protein in neurons adds to the evidence for CBD's potential neuroprotective properties, though this is limited to cell culture observations.
The Bigger Picture
The combination of anti-oxidant, anti-apoptotic, and anti-inflammatory properties makes CBD an interesting candidate for neuroprotection research. Multiple labs have explored CBD for neurodegenerative conditions, though the path from cell studies to clinical applications is long and uncertain.
What This Study Doesn't Tell Us
In vitro cell line study that may not translate to the complex environment of the living brain. The concentrations of CBD used may not be achievable in brain tissue. PC12 cells are a simplified model that does not capture the full complexity of Alzheimer's pathology.
Questions This Raises
- ?Can CBD achieve neuroprotective concentrations in human brain tissue?
- ?Does this anti-inflammatory mechanism translate to meaningful effects in animal models of Alzheimer's disease?
Trust & Context
- Key Stat:
- CBD blocked both p38 MAP kinase and NF-kappaB inflammatory pathways in beta-amyloid-exposed neurons
- Evidence Grade:
- In vitro cell study providing mechanistic evidence. Important for understanding potential pathways but far from clinical application.
- Study Age:
- Published in 2006. Research on CBD and neurodegeneration has continued, but clinical evidence for CBD in Alzheimer's treatment remains limited.
- Original Title:
- Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement.
- Published In:
- Neuroscience letters, 399(1-2), 91-5 (2006)
- Authors:
- Esposito, Giuseppe(3), De Filippis, Daniele(3), Maiuri, Maria Chiara, De Stefano, Daniela, Carnuccio, Rosa, Iuvone, Teresa
- Database ID:
- RTHC-00223
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can CBD treat Alzheimer's disease?
This cell study showed CBD can block inflammatory pathways triggered by Alzheimer's-related proteins, but this is a laboratory finding only. There is no clinical evidence that CBD treats or prevents Alzheimer's disease in humans.
How does CBD protect brain cells?
Previous research showed CBD has anti-oxidant and anti-apoptotic effects. This study added a third mechanism: CBD blocks the nitrosative stress pathway by inhibiting p38 MAP kinase and NF-kappaB, both key inflammatory mediators, in neurons exposed to beta-amyloid.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00223APA
Esposito, Giuseppe; De Filippis, Daniele; Maiuri, Maria Chiara; De Stefano, Daniela; Carnuccio, Rosa; Iuvone, Teresa. (2006). Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement.. Neuroscience letters, 399(1-2), 91-5.
MLA
Esposito, Giuseppe, et al. "Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement.." Neuroscience letters, 2006.
RethinkTHC
RethinkTHC Research Database. "Cannabidiol inhibits inducible nitric oxide synthase protein..." RTHC-00223. Retrieved from https://rethinkthc.com/research/esposito-2006-cannabidiol-inhibits-inducible-nitric
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.